Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma

Table 4 Comparison of baseline clinical data between Group A and Group B

	Group A (n = 40)	Group B (n = 36)	t/χ2 value	P value
Gender (Male)	29	26	0.001	0.978
Age (yr)	62.82 ± 12.93	64.82 ± 11.82	0.722	0.472
Tumor size (cm)	3.75 ± 1.21	3.13 ± 0.82	2.683	0.009
Number of tumors			0.002	0.961
Single	22
2-3	18	16
Child-Pugh classification			0.023	0.878
A	26	24
B	14	12
TBiL (μmol/L)	18.28 ± 5.28	17.38 ± 5.62	0.738	0.463
AFP (ng/ml)	612.29 ± 127.38	567.28 ± 92.39	1.746	0.085
ALB (g/L)	37.19 ± 5.39	34.94 ± 4.53	1.958	0.054
ALT (U/L)	35.27 ± 15.14	36.49 ± 12.31	0.383	0.703
AST (U/L)	38.63 ± 15.13	36.22 ± 13.26	0.735	0.465

AFP: Alpha-fetoprotein; ALB: Serum albumin; ALT: Aminotransferase; AST: Aspartate aminotransferase; TBiL: Total bilirubin.